期刊
DRUG DISCOVERY TODAY
卷 18, 期 23-24, 页码 1250-1255出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2013.07.002
关键词
-
资金
- UK BBSRC
- EPSRC
- Research Councils UK
- Lonza Biologics
- EPSRC [EP/H04986X/1] Funding Source: UKRI
- Engineering and Physical Sciences Research Council [EP/H04986X/1] Funding Source: researchfish
Despite decades of clinical and commercial success, the current paradigm for drug discovery and development is still empirical and costly. The many hundreds of therapeutic proteins (TPs) in the development pipeline and the FDA-led quality-by-design initiative represent opportunities to address this issue. Advances in our understanding of cellular mechanisms as well as the physicochemical and biological characteristics of TPs have enabled researchers to develop computational models that analyse or even predict molecular and cellular behaviour under different conditions. Coupled with new analytical tools, these models are increasingly used to systemise and expedite the design and optimisation of protein production processes throughout the discovery and development stages.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据